Masimo

[Image courtesy of Masimo]Masimo today announced it received CE mark approval for its LiDCO board-in-cable (BIC) module in hemodynamic monitoring.

The Irvine, California-based company designed LiDCO BIC to connect to multi-patient monitoring platforms, such as the Masimo Root Patient Monitoring and Connectivity Hub. It allows clinicians to easily add LiDCO hemodynamic monitoring with the company’s versatile PulseCO algorithm to its Root patient monitoring hubs.

LiDCO is pressure transducer agnostic and enables hemodynamic monitoring alongside other supported parameters without having a dedicated hemodynamic monitoring box. The module supports everything from powerful guided protocols to assess fluid responsiveness to rich trending data and notifications for beat-by-beat pressure analysis that can be displayed in helpful configurations for each patient, according to Masimo.

“Bringing LiDCO’s beat-to-beat advanced hemodynamic monitoring to Masimo Root o…

The Stork boot on a baby next to an image of the components of Stork. [Image courtesy of Masimo]Masimo (Nasdaq: MASI) + announced today that it initiated the full U.S. market release for its Stork home baby monitoring system.

Stork offers a continuous and accurate view of a baby’s health data. It leverages Masimo’s noninvasive neonate monitoring technologies. The Irvine, California-based company kicked off its initial launch for the system in May of this year.

“We are delighted to bring Masimo Stork to parents and caregivers in the United States,” said Joe Kiani, founder and CEO of Masimo. “With the launch of Stork, parents for the first time can have access to a technology originally developed for the most challenging patients in hospitals, with a user interface that is a simple and easy-to-use app on a phone.”

Features of Stork include noninvasive sensing technology that tracks pulse rate, oxygen satu…

Masimo  (Nasdaq: MASI) + shares fell this morning after the company shared second-quarter results that included reduced 2023 guidance.

Shares of MASI opened the day even at $120 apiece in the early morning. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — began the day relatively even as well.

The guidance cut comes as no surprise after the company startled Wall Street with preliminary results forecasting this last month. The new full-year guidance for Masimo’s healthcare business, previously set at $1.45 billion at the low end, dropped to $1.3 billion.

Masimo set the high end at $1.35 billion. It also cut non-healthcare sales guidance from $965 million to $995 million to $800 million to $850 million. Masimo projects full-year consolidated revenue to land between $2.1 billion and $2.2 billion.

“Second quarter 2023 was a tale of two realiti…

Root with SedLine brain function monitoring. [Image courtesy of Masimo]Masimo (Nasdaq: MASI) + today announced positive study findings from an evaluation of its SedLine brain function monitoring.

Dr. Lichy Han and colleagues at Stanford University evaluated SedLine, publishing their findings in Frontiers in Neuroscience. They looked at SedLine’s ability to assess the sedation levels of patients undergoing drug-induced sleep endoscopy (DISE) with dexmedetomidine.

Irvine, California-based Masimo said the researchers found that the Masimo Patient State Index (PSi), a SedLine parameter derived from electroencephalographic (EEG) data, was statistically significantly associated with dexmedetomidine dosage. Additionally, it better captured changes in brain state, the company said, and could potentially improve dexmedetomidine sedation monitoring.

According to researchers, anesthesia induced with dexmedetomidine may …

Masimo (Nasdaq: MASI) + announced preliminary second-quarter results that include a potentially significant reduction in sales guidance.

Full-year guidance for Masimo’s healthcare business, previously set at $1.45 billion at the low end, is expected to be slashed to $1.3 billion. The company said it is still evaluating the upper end of its guidance, which could land materially higher than the lower end. Masimo still targets its original guidance. It also expects cut its non-healthcare guidance from $965 million to $995 million to $800 million to $850 million.

The company also said it plans to take action to reduce costs in the second half of the year. It intends to share more details when it announces its complete financial results on Aug. 8.

For now, Irvine, California-based Masimo expects its quarterly revenues to range between $453 million and $457 million. That includes between $280 million and $282 mi…

The HEOS at-home monitoring technology, including the W1 watch. [Image courstey of Masimo]Masimo (Nasdaq:MASI) today announced the global expansion of its HEOS platform for always-on connection through its secure cloud.

The Masimo Health secure cloud covers 4 million devices, offering customers an enhanced health-tracking experience. This software upgrade enables Masimo’s devices and cloud solution to seamlessly integrate with HEOS-enabled devices. Those include sound bars, wireless speakers, amplifiers and receivers from Denon, Marantz and Definitive Technology.

Irvine, California-based Masimo plans to bring this expansion worldwide, including to the U.S. Canada, the UK, Japan and Australia, initially. It expects to take the software upgrade live in more countries later this year.

“We are excited to expand the footprint and capabilities of our HEOS platform with our wearables and provide our customers with health tracking truly integrated with their …

Masimo (Nasdaq: MASI) reported Street-beating first-quarter results and maintained its full-year 2023 guidance ahead of a proxy battle at the annual meeting of shareholders.

Investors reacted by sending MASI shares up 1% to $186.50 apiece in after-hours trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.

The Irvine, California–based company earned $21.3 million, or 39¢ per diluted share, off of $565.0 million in revenue for the quarter that ended March 31, 2023.

Adjusted to exclude one-time items, Masimo had a Q1 EPS of 87¢. The result came in 4¢ ahead of the predictions of Wall Street analysts, who expected earnings per share of 83¢ and $557.85 million in revenue.

“Our strong performance this quarter reflects our long track record of innovation in our professional healthcare business, our thoughtful stewardship of our established luxury and prem…